mRNA vaccine delivery using lipid nanoparticles

Therapeutic Delivery

Volumn 7, Issue 5, 2016, Pages 319-334

  Reichmuth, Andreas M ^a,b   Oberli, Matthias A ^a,b   Jeklenec, Ana ^b   Langer, Robert ^a,b,c   Blankschtein, Daniel ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

adjuvant; cancer immunotherapy; cationic lipid; drug delivery; lipid nanoparticle; mRNA; oligonucleotide; therapeutic vaccine; vaccine

Indexed keywords

DNA VACCINE; MRNA VACCINE; RNA VACCINE; SOLID LIPID NANOPARTICLE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; LIPID; MESSENGER RNA; NANOPARTICLE; VACCINE;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG SYNTHESIS; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; NONHUMAN; PRIORITY JOURNAL; VACCINATION; ANIMAL; DRUG DELIVERY SYSTEM; MACACA; MOUSE; PROCEDURES; RABBITS AND HARES;

ANIMALS; DRUG DELIVERY SYSTEMS; LIPIDS; MACACA; MICE; NANOPARTICLES; RABBITS; RNA, MESSENGER; VACCINES;

EID: 84964930086     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde-2016-0006     Document Type: Article

References (145)

1. Crawford N W, Bines JE, Royle J, Buttery JP. Optimizing immunization in pediatric special risk groups. Expert Rev. Vaccines 10(2), 175-186 (2011).
2. Liu MA. Immunologic basis of vaccine vectors. Immunity 33(4), 504-515 (2010).
3. Hilleman MR. Recombinant vector vaccines in vaccinology. Dev. Biol. Stand. 82, 3-20 (1994).
4. Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin. Drug Deliv. 11(6), 885-899 (2014).
5. Pascolo S. Vaccination with messenger RNA (mRNA). In: Toll-Like Receptors (TLRs) and Innate Immunity. Bauer PDS, Hartmann PDG (Eds). Springer Berlin Heidelberg, Germany 221-235 (2008).
6. Jäschke A, Helm M. RNA sex. Chem. Biol. 10(12), 1148-1150 (2003).
7. Fotin-Mleczek M, Duchardt KM, Lorenz C et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34(1), 1-15 (2011).
8. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine 29(17), 3341-3355 (2011).
9. Sorrentino S. Human extracellular ribonucleases: multiplicity, molecular diversity and catalytic properties of the major RNase types. Cell. Mol. Life Sci. CMLS 54(8), 785-794 (1998).
10. Chira S, Jackson CS, Oprea I et al. Progresses towards safe and effcient gene therapy vectors. Oncotarget 6 (31), 30675-30703 (2015).
11. Ku SH, Jo SD, Lee YK, Kim K, Kim SH. Chemical and structural modifcations of RNAi therapeutics. Adv. Drug Deliv. Rev. doi:10.1016/j.addr.2015.10.015 (2015) (Epub ahead of print).
12. Lundstrom K. Alphaviruses in gene therapy. Viruses 1(1), 13-25 (2009).
13. Ogris M, Brunner S, Schüller S, Kircheis R, Wagner E. PEGylated DNA/transferring-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6(4), 595-605 (1999).
14. Bessis N, GarciaCozar FJ, Boissier M-C. Immune responses to gene therapy vectors: infuence on vector function and effector mechanisms. Gene Ther. 11(S1), S10-S17 (2004).
15. Baum C, Kustikova O, Modlich U, Li Z, Fehse B. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum. Gene Ther. 17(3), 253-263 (2006).
16. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet. 8(8), 573-587 (2007).
17. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4(5), 346-358 (2003).
18. Bouard D, Alazard-Dany N, Cosset F-L. Viral vectors: from virology to transgene expression. Br. J. Pharmacol. 157(2), 153-165 (2009).
19. Gonzalez H, Hwang SJ, Davis ME. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug. Chem. 10 (6), 1068-1074 (1999).
20. Davis ME. The First Targeted Delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6(3), 659-668 (2009).
21. Monopoli MP, Åberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7(12), 779-786 (2012).
22. Lee H, Lytton-Jean AKR, Chen Y et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat. Nanotechnol. 7(6), 389-393 (2012).
23. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem. Rev. 109(2), 259-302 (2009).
24. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat. Rev. Drug Discov. 4(7), 581-593 (2005).
25. Martin ME, Rice KG. Peptide-guided gene delivery. AAPS J. 9(1), E18-E29 (2007).
26. Sokolova V, Epple M. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew. Chem. Int. Ed. 47(8), 1382-1395 (2008).
27. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8(2), 129-138 (2009).
28. Heath WR, Carbone FR. Cross-presentation in viral immunity and self-tolerance. Nat. Rev. Immunol. 1(2), 126-134 (2001).
29. Kasturi SP, Pulendran B. Cross-presentation: avoiding traffcking chaos? Nat. Immunol. 9(5), 461-463 (2008).
30. Martinon F, Krishnan S, Lenzen G et al. Induction of virus-specifc cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 23(7), 1719-1722 (1993).
31. Hess PR, Boczkowski D, Nair SK, Snyder D, Gilboa E. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor effciently primes CTL responses, but is insuffcient to overcome tolerance to a model tumor/self antigen. Cancer Immunol. Immunother. 55(6), 672-683 (2005).
32. Zhou W-Z, Hoon DSB, Huang SKS et al. RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. Hum. Gene Ther. 10(16), 2719-2724 (1999).
33. Pollard C, Rejman J, De Haes W et al. Type I IFN counteracts the induction of antigen-specifc immune responses by lipid-based delivery of mRNA vaccines. Mol. Ther. 21(1), 251-259 (2013).
34. Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specifc cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 30(1), 1-7 (2000).
35. Mockey M, Bourseau E, Chandrashekhar V et al. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 14(9), 802-814 (2007).
36. Perche F, Benvegnu T, Berchel M et al. Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomed. Nanotechnol. Biol. Med. 7(4), 445-453 (2011).
37. Phua KKL, Staats HF, Leong KW, Nair SK. Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Sci. Rep. 4, 5128 (2014).
38. Geall AJ, Verma A, Otten GR et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl Acad. Sci. USA 109(36), 14604-14609 (2012).
39. Brito LA, Chan M, Shaw CA et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. 22(12), 2118-2129 (2014).
40. Li W, Jr FCS. Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res. 24(3), 438-449 (2007).
41. Kuntsche J, Horst JC, Bunjes H. Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems. Int. J. Pharm. 417(1), 120-137 (2011).
42. Zhigaltsev IV, Maurer N, Edwards K, Karlsson G, Cullis PR. Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J. Control. Rel. 110(2), 378-386 (2006).
43. Sato Y, Hatakeyama H, Sakurai Y, Hyodo M, Akita H, Harashima H. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. J. Control. Rel. 163(3), 267-276 (2012).
44. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat. Mater. 12(11), 967-977 (2013).
45. Basha G, Novobrantseva TI, Rosin N et al. Infuence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of sirna in antigen-presenting cells. Mol. Ther. 19(12), 2186-2200 (2011).
46. Sahay G, Querbes W, Alabi C et al. Effciency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol. 31(7), 653-658 (2013).
47. Semple SC, Akinc A, Chen J et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28(2), 172-176 (2010).
48. Maier MA, Jayaraman M, Matsuda S et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21(8), 1570-1578 (2013).
49. Jayaraman M, Ansell SM, Mui BL et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl. 51(34), 8529-8533 (2012).
50. Love KT, Mahon KP, Levins CG et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107(5), 1864-1869 (2010).
51. Whitehead KA, Dorkin JR, Vegas AJ et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun. 5, 4277 (2014).
52. Dong Y, Love KT, Dorkin JR et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl Acad. Sci. USA 111(11), 3955-3960 (2014).
53. Cui L, Chen D, Zhu L. Conformation transformation determined by different self-assembled phases in a DNA complex with cationic polyhedral oligomeric silsesquioxane lipid. ACS Nano 2(5), 921-927 (2008).
54. Dobbs W, Heinrich B, Bourgogne C et al. Mesomorphic imidazolium salts: new vectors for effcient siRNA transfection. J. Am. Chem. Soc. 131(37), 13338-13346 (2009).
55. Smisterová J, Wagenaar A, Stuart MCA et al. Molecular shape of the cationic lipid controls the structure of cationic lipid/dioleylphosphatidylethanolamine-DNA complexes and the effciency of gene delivery. J. Biol. Chem. 276(50), 47615-47622 (2001).
56. Hirsch-Lerner D, Zhang M, Eliyahu H, Ferrari ME, Wheeler CJ, Barenholz Y. Effect of 'helper lipid' on lipoplex electrostatics. Biochim. Biophys. Acta BBA-Biomembr. 1714(2), 71-84 (2005).
57. Koiwai K, Tokuhisa K, Karinaga R et al. Transition from a normal to inverted cylinder for an amidine-bearing lipid/pDNA complex and its excellent transfection. Bioconjug. Chem. 16(6), 1349-1351 (2005).
58. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65(1), 36-48 (2013).
59. Lu JJ, Langer R, Chen J. A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery. Mol. Pharm. 6(3), 763-771 (2009).
60. Takahashi H, Sinoda K, Hatta I. Effects of cholesterol on the lamellar and the inverted hexagonal phases of dielaidoylphosphatidylethanolamine. Biochim. Biophys. Acta 1289(2), 209-216 (1996).
61. Zuhorn IS, Bakowsky U, Polushkin E et al. Nonbilayer phase of lipoplex-membrane mixture determines endosomal escape of genetic cargo and transfection effciency. Mol. Ther. 11(5), 801-810 (2005).
62. Woodle MC. Sterically stabilized liposome therapeutics. Adv. Drug Deliv. Rev. 16(2), 249-265 (1995).
63. Belliveau NM, Huft J, Lin PJ et al. Microfuidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol. Ther. Nucleic Acids 1(8), e37 (2012).
64. Li S-D, Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J. Control. Rel. Off. J. Control Rel. Soc. 145(3), 178-181 (2010).
65. Buyens K, De Smedt SC, Braeckmans K et al. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J. Control Rel. 158(3), 362-370 (2012).
66. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440(7085), 808-812 (2006).
67. Schlosser E, Mueller M, Fischer S et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26(13), 1626-1637 (2008).
68. Lasic DD. The mechanism of vesicle formation. Biochem. J. 256(1), 1-11 (1988).
69. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv. Pharm. Bull. 5(3), 305-313 (2015).
70. Zhigaltsev IV, Belliveau N, Hafez I et al. Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfuidic mixing. Langmuir 28(7), 3633-3640 (2012).
71. Huang C-H. Phosphatidylcholine vesicles. Formation and physical characteristics. Biochemistry (Mosc.) 8(1), 344-352 (1969).
72. Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim. Biophys. Acta BBA-Biomembr. 298(4), 1015-1019 (1973).
73. Semple SC, Klimuk SK, Harasym TO et al. Effcient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta BBA-Biomembr. 1510(1), 152-166 (2001).
74. Maurer N, Wong KF, Stark H et al. Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys. J. 80(5), 2310-2326 (2001).
75. Berger N, Sachse A, Bender J, Schubert R, Brandl M. Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation effciency, and process characteristics. Int. J. Pharm. 223(1), 55-68 (2001).
76. Jeffs LB, Palmer LR, Ambegia EG, Giesbrecht C, Ewanick S, MacLachlan I. A scalable, extrusion-free method for effcient liposomal encapsulation of plasmid DNA. Pharm. Res. 22(3), 362-372 (2005).
77. Karnik R, Gu F, Basto P et al. Microfuidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett. 8(9), 2906-2912 (2008).
78. Jahn A, Vreeland WN, DeVoe DL, Locascio LE, Gaitan M. Microfuidic directed formation of liposomes of controlled size. Langmuir 23(11), 6289-6293 (2007).
79. Stroock AD, Dertinger SKW, Ajdari A, MeziC I, Stone HA, Whitesides GM. Chaotic mixer for microchannels. Science 295(5555), 647-651 (2002).
80. Leung AKK, Tam YYC, Chen S, Hafez IM, Cullis PR. Microfuidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems. J. Phys. Chem. B 119(28), 8698-8706 (2015).
81. Swartz MA. The physiology of the lymphatic system. Adv. Drug Deliv. Rev. 50(1), 3-20 (2001).
82. Allen TM, Hansen CB, Guo LSS. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim. Biophys. Acta BBA-Biomembr. 1150(1), 9-16 (1993).
83. Oussoren C, Velinova M, Scherphof G, van der Want JJ, van Rooijen N, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: IV. Fate of liposomes in regional lymph nodes. Biochim. Biophys. Acta BBA-Biomembr. 1370(2), 259-272 (1998).
84. Henriksen-Lacey M, Bramwell VW, Christensen D, Agger E-M, Andersen P, Perrie Y. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J. Control. Rel. 142(2), 180-186 (2010).
85. Henriksen-Lacey M, Christensen D, Bramwell VW et al. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[n-(n′, n′-dimethylaminoethane)carbomyl], cholesterol (DC-Chol), and 1, 2-dioleoyl-3-trimethylammonium propane (dotap): prolonged liposome retention mediates stronger Th1 responses. Mol. Pharm. 8(1), 153-161 (2011).
86. Ishida T, Harashima H, Kiwada H. Liposome clearance. Biosci. Rep. 22(2), 197-224 (2002).
87. Carstens MG, Camps MGM, Henriksen-Lacey M et al. Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. Vaccine 29(29), 4761-4770 (2011).
88. Kaur R, Bramwell VW, Kirby DJ, Perrie Y. Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses. J. Control Rel. 158(1), 72-77 (2012).
89. van den Berg JH, Oosterhuis K, Hennink WE et al. Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. J. Control Rel. 141(2), 234-240 (2010).
90. Mishra S, Webster P, Davis ME. PEGylation signifcantly affects cellular uptake and intracellular traffcking of non-viral gene delivery particles. Eur. J. Cell Biol. 83 (3), 97-111 (2004).
91. Remaut K, Lucas B, Braeckmans K, Demeester J, De Smedt SC. Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides. J. Control Rel. 117(2), 256-266 (2007).
92. Yang Q, Lai SK. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7(5), 655-677 (2015).
93. Judge A, McClintock K, Phelps JR, MacLachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther. 13(2), 328-337 (2006).
94. Martinez-Pomares L. The mannose receptor. J. Leukoc. Biol. 92 (6), 1177-1186 (2012).
95. Geijtenbeek TBH, Torensma R, van Vliet SJ et al. Identifcation of DC-SIGN, a novel dendritic cell-specifc ICAM-3 receptor that supports primary immune responses. Cell 100(5), 575-585 (2000).
96. Jiang W, Swiggard WJ, Heufer C et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375 (6527), 151-155 (1995).
97. Valladeau J, Ravel O, Dezutter-Dambuyant C et al. Langerin, a novel C-Type lectin specifc to langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12(1), 71-81 (2000).
98. Karanikas V, Hwang LA, Pearson J et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100(11), 2783-2792 (1997).
99. Espuelas S, Thumann C, Heurtault B, Schuber F, Frisch B. Infuence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes. Bioconjug. Chem. 19(12), 2385-2393 (2008).
100. Reina JJ, Rojo J. Glycodendritic structures: tools to interact with DC-SIGN. Braz. J. Pharm. Sci. 49(SPE), 109-124 (2013).
101. Perche F, Gosset D, Mével M et al. Selective gene delivery in dendritic cells with mannosylated and histidylated lipopolyplexes. J. Drug Target. 19(5), 315-325 (2011).
102. Dudziak D, Kamphorst AO, Heidkamp GF et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315(5808), 107-111 (2007).
103. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28(Suppl. 3), C25-C36 (2010).
104. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59(6), 478-490 (2007).
105. Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Tolllike receptor 4 in immune activation. Biomaterials 31(26), 6867-6875 (2010).
106. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34(5), 637-650 (2011).
107. Yanasarn N, Sloat BR, Cui Z. Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens. Mol. Pharm. 8 (4), 1174-1185 (2011).
108. Adler-Moore J, Munoz M, Kim H et al. Characterization of the murine Th2 response to immunization with liposomal M2e infuenza vaccine. Vaccine 29(27), 4460-4468 (2011).
109. Ravindran R, Maji M, Ali N. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. Mol. Pharm. 9(1), 59-70 (2012).
110. Rizwan SB, McBurney WT, Young K et al. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses. J. Control Rel. 165(1), 16-21 (2013).
111. Shirota H, Klinman DM. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Exp. Rev. Vaccines 13(2), 299-312 (2014).
112. Erikçi E, Gursel M, Gürsel I. Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes. Biomaterials 32(6), 1715-1723 (2011).
113. Bal SM, Hortensius S, Ding Z, Jiskoot W, Bouwstra JA. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Vaccine 29(5), 1045-1052 (2011).
114. Wu TY-H, Singh M, Miller AT et al. Rational design of small molecules as vaccine adjuvants. Sci. Transl. Med. 6(263), 263ra160-263ra160 (2014).
115. Jensen S, Thomsen AR. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J. Virol. 86(6), 2900-2910 (2012).
116. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics-developing a new class of drugs. Nat. Rev. Drug Discov. 13(10), 759-780 (2014).
117. Balachandran S, Roberts PC, Brown LE et al. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 13(1), 129-141 (2000).
118. Banerjee S, Chakrabarti A, Jha BK et al. Cell-type-specifc effects of RNase L on viral induction of beta interferon. mBio 5(2), e00856-e00814 (2014); doi: 10.1128/mBio.00856-14.
119. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modifcation and the evolutionary origin of RNA. Immunity 23 (2), 165-175 (2005).
120. Karikó K, Muramatsu H, Welsh FA et al. Incorporation of pseudouridine into mrna yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. J. Am. Soc. Gene Ther. 16(11), 1833-1840 (2008).
121. Kübler H, Scheel B, Gnad-Vogt U et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a frst-in-man Phase I/IIa study. J. Immunother. Cancer 3(1), 26 (2015).
122. Riedmann EM. Human vaccines and immunotherapeutics. Hum. Vaccines Immunother. 9(10), 2034-2037 (2013).
123. Peabody DS. Translation initiation at non-AUG triplets in mammalian cells. J. Biol. Chem. 264(9), 5031-5035 (1989).
124. Malarkannan S, Horng T, Shih PP, Schwab S, Shastri N. Presentation of out-of-frame peptide/MHC Class I complexes by a novel translation initiation mechanism. Immunity 10(6), 681-690 (1999).
125. Mauro VP, Chappell SA. A critical analysis of codon optimization in human therapeutics. Trends Mol. Med. 20(11), 604-613 (2014).
126. Litzinger DC, Buiting AMJ, van Rooijen N, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys. Acta BBA-Biomembr. 1190(1), 99-107 (1994).
127. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10(11), 787-796 (2010).
128. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfde) nanoparticles. J. Control Rel. 112(1), 26-34 (2006).
129. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38(5), 1404-1413 (2008).
130. Midoux P, Pichon C. Lipid-based mRNA vaccine delivery systems. Expert Rev. Vaccines 14(2), 221-234 (2015).
131. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of infuenza vaccine. N. Engl. J. Med. 351(22), 2295-2301 (2004).
132. Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal infuenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350(9), 896-903 (2004).
133. Kreiter S, Selmi A, Diken M et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 70(22), 9031-9040 (2010).
134. Tagawa ST, Lee P, Snively J et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma. Cancer 98(1), 144-154 (2003).
135. Pardi N, Tuyishime S, Muramatsu H et al. Expression kinetics of nucleoside-modifed mRNA delivered in lipid nanoparticles to mice by various routes. J. Control Rel. 217, 345-351 (2015).
136. McCullough KC, Milona P, Thomann-Harwood L et al. Self-amplifying replicon RNA vaccine delivery to dendritic cells by synthetic nanoparticles. Vaccines 2(4), 735-754 (2014).
137. Ulmer JB, Mason PW, Geall A, Mandl CW. RNA-based vaccines. Vaccine 30(30), 4414-4418 (2012).
138. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239(2), 389-401 (1997).
139. ® vaccine against H7N9 infuenza is immunogenic in mice. Emerg. Microbes Infect. 2(8), e52 (2013).
140. Weide B, Pascolo S, Scheel B et al. Direct injection of protamine-protected mRNA: results of a Phase 1/2 vaccination trial in metastatic melanoma patients. J. Immunother. 32(5), 498-507 (2009).
141. Xue HY, Guo P, Wen W-C, Wong HL. Lipid-based nanocarriers for RNA delivery. Curr. Pharm. Des. 21(22), 3140-3147 (2015).
142. Kauffman KJ, Dorkin JR, Yang JH et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and defnitive screening designs. Nano Lett. 15(11), 7300-7306 (2015).
143. MacGregor RR, Boyer JD, Ugen KE et al. First human trial of a DNA-based vaccine for treatment of human immunodefciency virus type 1 infection: safety and host response. J. Infect. Dis. 178(1), 92-100 (1998).
144. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 53(3), 296-302 (2011).
145. Weide B, Garbe C, Rammensee H-G, Pascolo S. Plasmid DNA-and messenger RNA-based anti-cancer vaccination. Immunol. Lett. 115(1), 33-42 (2008).